Literature DB >> 23090447

Risk factors: Plasma renin activity predicts renal impairment.

Thomas Unger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23090447     DOI： 10.1038/nrneph.2012.243

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).

Authors:  Serge Masson; Scott Solomon; Laura Angelici; Roberto Latini; Inder S Anand; Margaret Prescott; Aldo P Maggioni; Gianni Tognoni; Jay N Cohn
Journal:  J Card Fail       Date:  2010-12       Impact factor: 5.712

2.  Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors:  Harvey D White; Philip E G Aylward; Zhen Huang; Anthony J Dalby; W Douglas Weaver; Ståle Barvik; José Antonio Marin-Neto; Jan Murin; Rolf O Nordlander; Wiek H van Gilst; Faiez Zannad; John J V McMurray; Robert M Califf; Marc A Pfeffer
Journal:  Circulation       Date:  2005-11-21       Impact factor: 29.690

3.  Essential hypertension: renin and aldosterone, heart attack and stroke.

Authors:  H R Brunner; J H Laragh; L Baer; M A Newton; F T Goodwin; L R Krakoff; R H Bard; F R Bühler
Journal:  N Engl J Med       Date:  1972-03-02       Impact factor: 91.245

4.  Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.

Authors:  Giuliano Tocci; Francesco Paneni; Francesca Palano; Sebastiano Sciarretta; Andrea Ferrucci; Theodore Kurtz; Giuseppe Mancia; Massimo Volpe
Journal:  Am J Hypertens       Date:  2011-02-17       Impact factor: 2.689

5.  A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein.

Authors:  Jan H Schefe; Mario Menk; Jana Reinemund; Karin Effertz; Robin M Hobbs; Pier Paolo Pandolfi; Patricia Ruiz; Thomas Unger; Heiko Funke-Kaiser
Journal:  Circ Res       Date:  2006-11-02       Impact factor: 17.367

6.  Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.

Authors:  Jean E Sealey; John H Laragh
Journal:  Am J Hypertens       Date:  2007-05       Impact factor: 2.689

7.  Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.

Authors:  M H Alderman; S Madhavan; W L Ooi; H Cohen; J E Sealey; J H Laragh
Journal:  N Engl J Med       Date:  1991-04-18       Impact factor: 91.245

8.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

9.  Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

Authors:  Peter S Sever; Choon L Chang; Margaret F Prescott; Ajay Gupta; Neil R Poulter; Andrew Whitehouse; Michael Scanlon
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.